Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep;37(37):e2501526.
doi: 10.1002/adma.202501526. Epub 2025 Jun 25.

Extracellular Matrix Topography Drives Adrenergic to Mesenchymal Transition in Neuroblastoma

Affiliations

Extracellular Matrix Topography Drives Adrenergic to Mesenchymal Transition in Neuroblastoma

Antonios Chronopoulos et al. Adv Mater. 2025 Sep.

Abstract

Neuroblastoma (NB), the most common extracranial solid tumor in children, exhibits intra-tumoral heterogeneity with two interconvertible identities: adrenergic (ADRN) and mesenchymal (MES). Compared to ADRN cells, MES cells exhibit phenotypes associated with metastasis and therapy resistance. Thus, the transition from ADRN to MES may contribute to poor clinical outcomes, necessitating further investigation into this ADRN-to-MES transition (AMT) to improve clinical responses. The extracellular matrix (ECM), a critical component of the tumor microenvironment (TME), provides structural support and delivers mechanical signals that influence oncogenic processes. This research demonstrates that high-risk NB tumors contain more topographically aligned ECM fibers than low-risk NB tumors. Using nano-fabricated biomaterials designed to mimic the aligned ECM, ECM topography is revealed to drive AMT through transcriptional and epigenetic changes, accompanied by enhanced MES phenotypic features. Furthermore, ECM topography is shown to stimulate Rho-associated kinase and YAP signaling pathways, which mediate ECM-driven reprogramming. These findings introduce ECM-driven AMT as a novel mechanism in NB progression and provide insights into TME-targeted therapeutic strategies aimed at suppressing MES cells to improve clinical outcomes in NB.

Keywords: YAP; adrenergic to mesenchymal transition; extracellular matrix; neuroblastoma; rho‐kinase.

PubMed Disclaimer

References

    1. V. Boeva, C. Louis‐Brennetot, A. Peltier, S. Durand, C. Pierre‐Eugène, V. Raynal, H. C. Etchevers, S. Thomas, A. Lermine, E. Daudigeos‐Dubus, B. Geoerger, M. F. Orth, T. G. P. Grünewald, E. Diaz, B. Ducos, D. Surdez, A. M. Carcaboso, I. Medvedeva, T. Deller, V. Combaret, E. Lapouble, G. Pierron, S. Grossetête‐Lalami, S. Baulande, G. Schleiermacher, E. Barillot, H. Rohrer, O. Delattre, I. Janoueix‐Lerosey, Nat. Genet. 2017, 49, 1408.
    1. M. Gautier, C. Thirant, O. Delattre, I. Janoueix‐Lerosey, Cancers (Basel) 2021, 13, 2904.
    1. T. van Groningen, J. Koster, L. J. Valentijn, D. A. Zwijnenburg, N. Akogul, N. E. Hasselt, M. Broekmans, F. Haneveld, N. E. Nowakowska, J. Bras, C. J. M. van Noesel, A. Jongejan, A. H. van Kampen, L. Koster, F. Baas, L. van Dijk‐Kerkhoven, M. Huizer‐Smit, M. C. Lecca, A. Chan, A. Lakeman, P. Molenaar, R. Volckmann, E. M. Westerhout, M. Hamdi, P. G. van Sluis, M. E. Ebus, J. J. Molenaar, G. A. Tytgat, B. A. Westerman, J. van Nes, et al., Nat. Genet. 2017, 49, 1261.
    1. C. Thirant, A. Peltier, S. Durand, A. Kramdi, C. Louis‐Brennetot, C. Pierre‐Eugène, M. Gautier, A. Costa, A. Grelier, S. Zaïdi, N. Gruel, I. Jimenez, E. Lapouble, G. Pierron, D. Sitbon, H. J. Brisse, A. Gauthier, P. Fréneaux, S. Grossetête, L. G. Baudrin, V. Raynal, S. Baulande, A. Bellini, J. Bhalshankar, A. M. Carcaboso, B. Geoerger, H. Rohrer, D. Surdez, V. Boeva, G. Schleiermacher, et al., Nat. Commun. 2023, 14, 2575.
    1. E. M. Westerhout, M. Hamdi, P. Stroeken, N. E. Nowakowska, A. Lakeman, J. van Arkel, N. E. Hasselt, B. Bleijlevens, N. Akogul, F. Haneveld, A. Chan, P. van Sluis, D. Zwijnenburg, R. Volckmann, C. J. M. van Noesel, I. Adameyko, T. van Groningen, J. Koster, L. J. Valentijn, J. van Nes, R. Versteeg, Cancer Res. 2022, 82, 484.

Substances

LinkOut - more resources